XML 36 R22.htm IDEA: XBRL DOCUMENT v3.19.1

Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Debt Securities, Available-for-sale [Table Text Block]

		December 31, 2018
		Amortized Cost				Accrued Interest				Gross Unrealized Gains				Gross Unrealized Losses				Estimated Fair Value
Obligations of U.S. Government and its agencies		$	50,613			$	176			$	15			$	(131	)		$	50,673
Corporate debt securities			45,793				254				4				(171	)			45,880
Certificates of deposit			3,559				14				-				(14	)			3,559
Total investments		$	99,965			$	444			$	19			$	(316	)		$	100,112

		December 31, 2017
		Amortized Cost				Accrued Interest				Gross Unrealized Gains				Gross Unrealized Losses				Estimated Fair Value
Obligations of U.S. Government and its agencies		$	60,121			$	177			$	-			$	(122	)		$	60,176
Corporate debt securities			34,021				203				-				(108	)			34,116
Certificates of deposit			11,099				32				1				(14	)			11,118
Total investments		$	105,241			$	412			$	1			$	(244	)		$	105,410

Available For Sale Securities Debt Maturities Fair Value [Table Text Block]

		2018				2017
Maturing in one year or less		$	77,736			$	64,115
Maturing after one year through two years			22,376				34,257
Maturing after two years			-				7,038
Total investments		$	100,112			$	105,410

Schedule of Receivables from Collaborations [Table Text Block]

		December 31, 2018
		Billed				Unbilled				Total
U.S. Department of Health and Human Services		$	-			$	1,525			$	1,525
Shionogi & Co. Ltd.			854				-				854
Green Cross Corporation			876				28				904
Mundipharma International Holdings Limited			44				-				44
Seqirus UK Limited			940				26				966
Total receivables		$	2,714			$	1,579			$	4,293

		December 31, 2017
		Billed				Unbilled				Total
U.S. Department of Health and Human Services		$	42			$	2,020			$	2,062
Shionogi & Co. Ltd.			1,600				-				1,600
Green Cross Corporation			1,388				28				1,416
Mundipharma International Holdings Limited			47				-				47
Seqirus UK Limited			825				167				992
Total receivables		$	3,902			$	2,215			$	6,117

Schedule of Accrued Liabilities [Table Text Block]

		December 31,
		2018				2017
Compensation and benefits		$	4,659			$	2,905
Development costs			7,564				6,683
Inventory			1,649				-
Professional fees			118				729
Duties and taxes			51				148
Other			1,850				2,234
Total accrued expenses		$	15,891			$	12,699

Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]

		Balance at December 31, 2017				Adjustments due to ASC 606				Balance at January 1, 2018
Assets
Deferred collaboration expense		$	210			$	(58	)		$	152
Liabilities
Deferred revenue		$	8,484			$	(1,184	)		$	7,300
Equity
Accumulated deficit		$	(631,843	)		$	1,126			$	(630,717	)

		December 31, 2018
		As Reported				Adjustments due to ASC 606				Balances without adoption of ASC 606
Assets
Deferred collaboration expense		$	9			$	-			$	9
Liabilities
Deferred revenue		$	221			$	-			$	221
Equity
Accumulated deficit		$	(731,969	)		$	-			$	(731,969	)

		For the Twelve Months Ended December 31, 2018
		As Reported				Adjustments due to ASC 606				Balances without adoption of ASC 606
Collaborative and other research and development revenue		$	14,552			$	1,184			$	15,736
Research and development expenses			84,888				58				84,946
Net loss			(101,252	)			1,126				(100,126	)
Basic and diluted net loss per share		$	(0.98	)		$	0.01			$	(0.97	)

Disaggregation of Revenue [Table Text Block]

		2018				2017				2016
Product sales, net		$	-			$	1,501			$	2,269
Royalty revenue			6,101				10,543				9,682
Collaborative and other research and development revenues:
U.S. Department of Health and Human Services			2,552				4,608				12,449
Shionogi & Co. Ltd.			-				1,184				1,184
Seqirus UK Limited			12,000				7,350				769
Total collaborative and other research and development revenues			14,552				13,142				14,402
Total revenues		$	20,653			$	25,186			$	26,353

X

- Definition

Tabular disclosure of available for sale securities debt maturities fair value.

+ References

No definition available.

+ Details

Name:	bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock
Namespace Prefix:	bcrx_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure representing receivables from collaborations.

+ References

No definition available.

+ Details

Name:	bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock
Namespace Prefix:	bcrx_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI http://asc.fasb.org/topic&trid=2196928

+ Details

Name:	us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

+ Details

Name:	us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration